MAP2K7 and pancreatic neoplasm: GSK2141795 was tested in combination with the MEK inhibitor, GSK1120212, in pancreatic tumor xenografts to assess enhanced inhibition of tumor growth when the MAPK and AKT pathways are inhibited in unison [1], [17].